Loading
Personal cancer vaccines target a list of mutations, some present in only part of the tumour, so the tumour can escape by losing them. Restricting vaccines and T-cell products to clonal mutations shared by every tumour cell, identified by multi-region sequencing, should close that escape route.
Clonal (truncal) neoantigens are present in all tumour cells, so an immune response to them cannot be escaped by subclonal antigen loss. Multi-region sequencing or high-purity clonality inference can identify them. Personalised mRNA vaccines and clonal-neoantigen-reactive T-cell products (such as those pioneered from TRACERx data) could be restricted to clonal targets and compared with unselected designs.
Shares Moderna, BioNTech, Neoantigen, Personalised neoantigen (mRNA) vaccines.
Shares TIL therapy, Neoantigen, Personalised neoantigen (mRNA) vaccines.
Shares Moderna, BioNTech, Neoantigen, Personalised neoantigen (mRNA) vaccines.
Shares INTerpath-001 (V940-001), Moderna, Neoantigen, Personalised neoantigen (mRNA) vaccines.
Shares Moderna, BioNTech, Personalised neoantigen (mRNA) vaccines.
Shares INTerpath-001 (V940-001), BioNTech, Neoantigen, Personalised neoantigen (mRNA) vaccines.
Shares Neoantigen, Personalised neoantigen (mRNA) vaccines, No one can predict who responds to immunotherapy.